No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Eirion sees success in ‘first-in-man’ topical hair-loss therapy trial
The company says the early trial of its androgenic alopecia therapy saw patients benefit from six times more hair growth than placebo.
OliX administers first subject in trial of androgenic alopecia therapeutic
OLX72021 has the capability to suppress the hormone activity that leads to androgenic alopecia by minimising AR expressions.
Kintor doses first subject in US Phase I trial of dermatology asset
The trial is envisioned to progress the company's footprint in androgenetic alopecia and acne.
Kintor succeeds in Phase II study of US males with androgenetic alopecia
Kintor is gearing up for a Phase III clinical trial that will investigate KX-826 in the US-based male population.
Kintor concludes enrolment of Phase II alopecia trial in China
The randomised, double-blind trial will assess the safety and efficacy of KX-826 for AGA in female subjects.
Kintor concludes subject enrolment in Phase II acne vulgaris trial
The success rate of the treatment in each arm as per the five-point IGA scale by week 12 is the trial’s primary endpoint.
HopeMed advances its androgenetic alopecia treatment to Phase II trials
The China-based pharma has initiated Phase II recruitment following positive results for its prolactin receptor antibody in a Phase Ib study.
Kintor Pharma's GT20029 Phase II trial meets primary endpoint
The trial's primary endpoint was the change from baseline in non-vellus TAHC after 12 weeks of treatment compared to placebo.
Kintor begins dosing in androgenic alopecia treatment trial in China
The pivotal study will assess the safety and efficacy of KX-826 to treat male patients with AGA in China.
Kintor concludes Phase II androgenetic alopecia trial enrolment
The trial’s primary endpoint will be the change in non-vellus target area hair counts at week 24 from baseline.
Regulatory roundup: Alexion ALS drug sees approval prospects plummet
GlobalData’s Investigative News team reviews recent events that impacted a drug’s path to regulatory approval.
Kintor begins dosing Phase II androgenic alopecia treatment trial in US
The change from baseline in non-vellus target area hair counts at week 24 is the primary endpoint of the trial.
Kintor doses first subject in Phase III Covid-19 therapy trial in China
The trial will analyse the safety and efficacy of proxalutamide in male outpatients with Covid-19.